Medidata Solutions (MDSO) Lowered to Sell at Zacks Investment Research

Medidata Solutions (NASDAQ:MDSO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Medidata Solutions is a leading global provider of hosted clinical development solutions that enhance the efficiency of customers’ clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer), investigator benchmarking and budgeting (Medidata Grants Manager), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave). Medidata’s diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes some top global pharmaceutical companies. “

Several other equities analysts have also commented on the stock. ValuEngine lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Saturday, March 17th. TheStreet upgraded shares of Medidata Solutions from a “c+” rating to a “b-” rating in a research note on Monday, March 12th. Needham & Company LLC dropped their price target on shares of Medidata Solutions to $75.00 and set a “buy” rating on the stock in a research note on Friday, February 9th. Morgan Stanley dropped their price target on shares of Medidata Solutions from $86.00 to $79.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Finally, Royal Bank of Canada set a $82.00 price target on shares of Medidata Solutions and gave the company a “hold” rating in a research note on Thursday, February 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. Medidata Solutions currently has a consensus rating of “Buy” and an average target price of $82.07.



Shares of Medidata Solutions stock opened at $66.40 on Thursday. The company has a market capitalization of $3,844.24, a price-to-earnings ratio of 78.12, a P/E/G ratio of 3.41 and a beta of 1.53. Medidata Solutions has a 52 week low of $59.22 and a 52 week high of $85.92. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.49 and a current ratio of 1.49.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.10. The company had revenue of $141.20 million for the quarter, compared to analyst estimates of $140.65 million. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. The firm’s revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 earnings per share. analysts anticipate that Medidata Solutions will post 0.93 EPS for the current fiscal year.

In other news, CFO Rouven Bergmann sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $66.30, for a total transaction of $132,600.00. Following the transaction, the chief financial officer now directly owns 94,744 shares in the company, valued at $6,281,527.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Tarek Sherif sold 26,836 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $70.25, for a total transaction of $1,885,229.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,836 shares of company stock worth $2,495,689. Insiders own 5.80% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Xact Kapitalforvaltning AB acquired a new stake in shares of Medidata Solutions during the fourth quarter worth $424,000. Ashford Capital Management Inc. lifted its holdings in shares of Medidata Solutions by 1.7% during the fourth quarter. Ashford Capital Management Inc. now owns 178,895 shares of the company’s stock worth $11,337,000 after purchasing an additional 2,960 shares during the period. Disciplined Growth Investors Inc. MN lifted its holdings in shares of Medidata Solutions by 14.9% during the fourth quarter. Disciplined Growth Investors Inc. MN now owns 830,856 shares of the company’s stock worth $52,651,000 after purchasing an additional 107,701 shares during the period. MetLife Investment Advisors LLC acquired a new stake in shares of Medidata Solutions during the fourth quarter worth $4,000,000. Finally, Gotham Asset Management LLC acquired a new stake in shares of Medidata Solutions during the fourth quarter worth $431,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Medidata Solutions (MDSO) Lowered to Sell at Zacks Investment Research” was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://dakotafinancialnews.com/2018/04/12/medidata-solutions-mdso-lowered-to-sell-at-zacks-investment-research.html.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply